Fundraising FoxPhi Therapeutics
San Francisco, US · Delaware corporation
Find your way into Phi Therapeutics
Sign up to see every warm intro you have to Phi Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Phi Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Phitherapeutics (brand Phyla) develops patented bacteriophage-based skincare that targets acne-causing C. acnes bacteria while preserving the skin barrier and microbiome. Its phage treatment is marketed to consumers and recommended by licensed dermatologists and skin professionals.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$8.9M disclosed across 3 rounds · 2019–2023
▶$7.7MraisedJun 2024 · 22 investors · BiotechnologyRule 506(b)
- JUN LIDirector
- YUG VARMAExecutive Officer, Director
- NEIL GIUGNOExecutive Officer, Director
- KEVIN LAWDirector
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- Minimum investment
- $10K
- Proceeds to insiders
- $181.2K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$660KraisedJan 2022 · 7 investors · BiotechnologyRule 506(b)
- Jun LiDirector
- Yug VarmaExecutive Officer, Director, Promoter
- Maria ChoDirector, Promoter
- Offering amount
- $2M
- Amount sold
- $660K
- Minimum investment
- $10K
- Proceeds to insiders
- $50K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$575KraisedJun 2019 · 4 investors · BiotechnologyRule 506(b)
- Maria S. ChoExecutive Officer, Director
- Yug VarmaExecutive Officer, Director
- Jun LiDirector
- Offering amount
- $1.6M
- Amount sold
- $575K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $164.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Phi Therapeutics do?
- Phitherapeutics (brand Phyla) develops patented bacteriophage-based skincare that targets acne-causing C. acnes bacteria while preserving the skin barrier and microbiome. Its phage treatment is marketed to consumers and recommended by licensed dermatologists and skin professionals.
- How much funding has Phi Therapeutics raised?
- Phi Therapeutics has disclosed $8.9M raised across 3 rounds.
- Where is Phi Therapeutics headquartered?
- Phi Therapeutics is headquartered in San Francisco, US.